Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record.

Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass Spectrometry

Open access
Scott, C. Ronald, Elliott, Susan, Buroker, Norman, Thomas, Lauren I., Keutzer, Joan, Glass, Michael, Gelb, Michael H., Turecek, Frantisek · 2013 · The Journal of Pediatrics

Abstract

Objective To assess the performance of a tandem mass spectrometry technology in a newborn screening laboratory to simultaneously measure α-galactosidase, acid-α-glucosidase, and α-L-iduronidase for the detection of infants at risk to develop Fabry, Pompe, or Mucopolysaccharidosis-I (MPS-I) diseases. Study design Enzyme activity was assayed from a 3.2-mm punch from 100,000+ anonymous newborn blood spots. Punches with low enzyme activity were further evaluated by nucleotide sequence analysis of the responsible gene. Confirmation of affected infants was dependent on identification of mutations compatible with diminished enzyme activity. Results The technology for simultaneously measuring multiple enzyme activities by tandem mass spectrometry was successful. The confirmation of diagnosis for Fabry, Pompe, or MPS-I, by DNA sequencing estimated the prevalence of Fabry disease at 1/7,800 males (95% CI: 1/17,800 - 1/3,600); Pompe disease at 1/27,800 newborns (95% CI: 1/90,000 – 1/10,200); and MPS-I at 1/35,500 newborns (95% CI: 1/143,000 – 1/11,100). These estimates of prevalence are two to four times greater than the prevalence estimated by clinical diagnosis. The combined prevalence for the three disorders was 1/7,700 newborns (95% CI: 1/13,500 –1/4,500). Conclusions Tandem mass spectrometry for the simultaneous assay of multiple lysosomal enzymes can be successfully introduced into a routine newborn screening laboratory. The technology has a positive predictive value equal to, or better, than methods currently used for the detection of non-lysosomal disorders. Using newborn blood spots, the combined prevalence of Fabry, Pompe, and MPS-I is estimated at 1/7,700 newborns based on low-enzyme activity and confirmation by mutation analysis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jpeds.2013.01.031

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 159

Metadata

Authors
Scott, C. R., Elliott, S., Buroker, N., Thomas, L. I., Keutzer, J., Glass, M., Gelb, M. H., & Turecek, F.
Venue
The Journal of Pediatrics
Publisher
Elsevier BV
Published
2013-08
Volume
163
Issue
2
Pages
498-503
ISSN
0022-3476 (ISSN-L)
OpenAlex
W2109407008
Cited by
159
References
0
FWCI
12.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass Spectrometry. https://app.cochat.ai/papers/10.1016/j.jpeds.2013.01.031
The paper
Scott, C. R., Elliott, S., Buroker, N., Thomas, L. I., Keutzer, J., Glass, M., Gelb, M. H., & Turecek, F. (2013). Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass Spectrometry. The Journal of Pediatrics. https://doi.org/10.1016/j.jpeds.2013.01.031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.